Last reviewed · How we verify

Antiandrogen+docetaxel — Competitive Intelligence Brief

Antiandrogen+docetaxel (Antiandrogen+docetaxel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: androgen receptor antagonist + taxane chemotherapy. Area: Oncology.

phase 3 Combination therapy: androgen receptor antagonist + taxane chemotherapy Androgen receptor (AR) and microtubule-associated proteins Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Antiandrogen+docetaxel (Antiandrogen+docetaxel) — Göteborg University. This combination blocks androgen signaling while simultaneously disrupting microtubule dynamics to inhibit cancer cell proliferation and survival.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Antiandrogen+docetaxel TARGET Antiandrogen+docetaxel Göteborg University phase 3 Combination therapy: androgen receptor antagonist + taxane chemotherapy Androgen receptor (AR) and microtubule-associated proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: androgen receptor antagonist + taxane chemotherapy class)

  1. Göteborg University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antiandrogen+docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/antiandrogen-docetaxel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: